Home » Gene Synthesis & Molecular Biology Services » PD-L2 Fc Chimera, Human

PD-L2 Fc Chimera, Human

Name: Protein
Rating: 5 (6 reviews)

Collapse all
Expand all

Overview

Synonyms	B7-DC; bA574F11.2; Btdc; Butyrophilin B7-DC; Butyrophilin-like Protein; CD273 antigen; CD273; CD273PD-1 ligand 2; MGC142240; PD-1-ligand 2; PDCD1L2MGC142238; PDCD1LG2; PDL2; PD-L2
Description	PD-L1 and PD-L2 are ligands for PD-1, a costimulatory molecule that plays an inhibitory role in regulating T cell activation in the periphery. PD-L2 also known as PD-L2, B7-DC serves as a negative and a positive regulator of T cell function. The expression and function of PD-L2 are similar to PD-L1. Both PD-L2−PD-1 and PD-L1−PD-1 signals inhibit T cell proliferation by blocking cell cycle progression but not by increasing cell death. PD-L2−PD-1 interactions are able to inhibit TCR-mediated proliferation and cytokine production in the absence of CD28 costimulation. Threshold for T cell activation may be a balance between activating signals, such as those delivered by the engagement of CD28 by B7-1 and B7-2, and inhibitory signals, mediated by engagement of PD-1 by PD-L1 and PD-L2. The structural conservation of B7-like and CD28-like receptors may reflect the distance between T cells and APCs in the immunological synapse. The PD-L−PD-1 pathway may play a key role in the induction and/or maintenance of peripheral tolerance and autoimmune disease. Because PD-L1 and PD-L2 can inhibit effector T cell proliferation and cytokine production, the PD-L−PD-1 pathway may be an attractive therapeutic target. Blocking the PD-1 pathway may enhance anti-tumor immunity, whereas stimulating this pathway may be useful for down-regulating ongoing immune responses in transplant rejection and autoimmune and allergic diseases. Recombinant Human PD-L2 Fc Chimera produced in HEK293 cells is a polypeptide chain containing 432 amino acids with the C-termimal human IgG1 Fc fragment. A fully biologically active molecule, rhPD-L2 has a molecular mass of 75 kDa analyzed by reducing SDS-PAGE and is obtained by chromatographic techniques at GenScript.
Accession No	Q9BQ51
Species	Human
Source	HEK293
Biological Activity	Immobilized PD-L2 Fc Chimera, Human (Z03417) at 5 μg/mL (100 μL/well) can bind Biotin-PD-1 Fc, Human with a linear range of 2.44-39.06 ng/mL when detected by Streptavidin-HRP.
Sequence	LFTVTVPK ELYIIEHG SNVTLECN FDTGSHVN LGAITASL QKVENDTS PHRERATL LEEQLPLG KASFHIPQ VQVRDEGQ YQCIIIYG VAWDYKYL TLKVKASY RKINTHIL KVPETDEV ELTCQATG YPLAEVSW PNVSVPAN TSHSRTPE GLYQVTSV LRLKPPPG RNFSCVFW NTHVRELT LASIDLQS QMEPRTHP

Properties

Measured Molecular Weight	75 kDa, observed by reducing SDS-PAGE
Purity	> 97% as analyzed by reducing SDS-PAGE
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS, 5% trehalose and mannitol.
Reconstitution	Reconstituted in ddH₂O or PBS at 100 μg/ml
Endotoxin Level	< 0.2 EU/μg, determined by LAL method.
Storage	Lyophilized recombinant PD-L2 Fc Chimera, Human remains stable up to 6 months at lower than -70°C from date of receipt. Upon reconstitution, Human PD-L2 Fc Chimera should be stable up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.
Note	For research use only